image
Cytokinetics, Incorporated CYTK
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 37.019
-4.27 %
$ 4.42 B
Market Cap
-7.04
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one CYTK stock under the worst case scenario is HIDDEN Compared to the current market price of 37 USD, Cytokinetics, Incorporated is HIDDEN

CYTK Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one CYTK stock under the base case scenario is HIDDEN Compared to the current market price of 37 USD, Cytokinetics, Incorporated is HIDDEN

CYTK Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one CYTK stock under the best case scenario is HIDDEN Compared to the current market price of 37 USD, Cytokinetics, Incorporated is HIDDEN

CYTK Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart CYTK

image
1M 14.0%
6M -24%
1Y -55.0%
3Y -5%
5Y 53%
All
$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
18.5 M REVENUE
145.34%
Growth Rates
1Year 145.34%
3Years -35.99%
5Years -7.22%
7Years 4.73%
10Years -8.90%
-536 M OPERATING INCOME
-8.07%
Growth Rates
1Year -8.07%
3Years -42.25%
5Years -40.24%
7Years -24.85%
10Years -43.23%
-590 M NET INCOME
-12.03%
Growth Rates
1Year -12.03%
3Years -39.90%
5Years -37.10%
7Years -24.41%
10Years -44.70%
-396 M OPERATING CASH FLOW
4.45%
Growth Rates
1Year 4.45%
3Years -40.57%
5Years -34.21%
7Years -21.42%
10Years -24.33%
-553 M INVESTING CASH FLOW
-231.18%
Growth Rates
1Year -231.18%
3Years -55.26%
5Years -49.24%
7Years -35.54%
10Years -63.51%
931 M FINANCING CASH FLOW
320.49%
Growth Rates
1Year 320.49%
3Years 42.74%
5Years 42.25%
7Years 22.41%
10Years 34.25%
1.58 M REVENUE
-90.67%
Growth Rates
1Year 145.34%
3Years -35.99%
5Years -7.22%
7Years 4.73%
10Years -8.90%
-156 M OPERATING INCOME
-11.93%
Growth Rates
1Year -8.07%
3Years -42.25%
5Years -40.24%
7Years -24.85%
10Years -43.23%
-161 M NET INCOME
-7.57%
Growth Rates
1Year -12.03%
3Years -39.90%
5Years -37.10%
7Years -24.41%
10Years -44.70%
-132 M OPERATING CASH FLOW
-100.73%
Growth Rates
1Year 4.45%
3Years -40.57%
5Years -34.21%
7Years -21.42%
10Years -24.33%
106 M INVESTING CASH FLOW
-4.43%
Growth Rates
1Year -231.18%
3Years -55.26%
5Years -49.24%
7Years -35.54%
10Years -63.51%
4.75 M FINANCING CASH FLOW
99.41%
Growth Rates
1Year 320.49%
3Years 42.74%
5Years 42.25%
7Years 22.41%
10Years 34.25%
Balance Sheet Cytokinetics, Incorporated
image
Current Assets 1.11 B
Cash & Short-Term Investments 1.08 B
Receivables 16.6 M
Other Current Assets 15.3 M
Non-Current Assets 294 M
Long-Term Investments 145 M
PP&E 141 M
Other Non-Current Assets 7.7 M
76.77 %10.35 %10.06 %Total Assets$1.4b
Current Liabilities 180 M
Accounts Payable 20.4 M
Short-Term Debt 30.5 M
Other Current Liabilities 129 M
Non-Current Liabilities 1.36 B
Long-Term Debt 758 M
Other Non-Current Liabilities 599 M
8.38 %49.33 %38.98 %Total Liabilities$1.5b
EFFICIENCY
Earnings Waterfall Cytokinetics, Incorporated
image
Revenue 18.5 M
Cost Of Revenue 9.53 M
Gross Profit 8.94 M
Operating Expenses 555 M
Operating Income -536 M
Other Expenses 53.3 M
Net Income -590 M
100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)18m(10m)9m(555m)(536m)(53m)(590m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
48.41% GROSS MARGIN
48.41%
Averages
1Year 48.41%
3Years -1463.43%
5Years -918.21%
7Years -713.51%
10Years -558.82%
-2902.72% OPERATING MARGIN
-2902.72%
Averages
1Year -2902.72%
3Years -3278.39%
5Years -2053.60%
7Years -1559.75%
10Years -1187.95%
-3191.11% NET MARGIN
-3191.11%
Averages
1Year -3191.11%
3Years -3535.11%
5Years -2248.69%
7Years -1733.66%
10Years -1320.70%
435.49% ROE
435.49%
Averages
1Year 435.49%
3Years 314.93%
5Years 140.13%
7Years 236.23%
10Years 150.00%
-42.06% ROA
-42.06%
Averages
1Year -42.06%
3Years -48.52%
5Years -41.02%
7Years -43.84%
10Years -37.31%
-42.81% ROIC
-42.81%
Averages
1Year -42.81%
3Years -48.04%
5Years -38.84%
7Years -40.97%
10Years -36.03%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cytokinetics, Incorporated
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)(450m)(450m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -590 M
Depreciation & Amortization 9.53 M
Capital Expenditures -3.91 M
Stock-Based Compensation 97.8 M
Change in Working Capital 35.7 M
Others 106 M
Free Cash Flow -400 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cytokinetics, Incorporated
image
Wall Street analysts predict an average 1-year price target for CYTK of $75.5 , with forecasts ranging from a low of $55 to a high of $120 .
CYTK Lowest Price Target Wall Street Target
55 USD 48.57%
CYTK Average Price Target Wall Street Target
75.5 USD 103.95%
CYTK Highest Price Target Wall Street Target
120 USD 224.16%
Price
Max Price Target
Min Price Target
Average Price Target
12012011011010010090908080707060605050404030302020Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Cytokinetics, Incorporated
image
Sold
0-3 MONTHS
2.8 M USD 6
3-6 MONTHS
8.56 M USD 5
6-9 MONTHS
2.74 M USD 4
9-12 MONTHS
6.27 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, whose employment commenced in June and July 2025 as a material inducement to their employment. globenewswire.com - 4 days ago
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 Hot Line Presentation of MAPLE-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy globenewswire.com - 1 week ago
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2025 it granted stock options to purchase an aggregate of 83,583 shares of common stock and 56,334 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 11 employees, whose employment commenced in May and June, 2025, as a material inducement to their employment. globenewswire.com - 1 month ago
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - CYTK NEW YORK, NY / ACCESS Newswire / June 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. accessnewswire.com - 1 month ago
CYTK ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. accessnewswire.com - 1 month ago
Lost Money on Cytokinetics, Incorporated(CYTK)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky NEW YORK, NY / ACCESS Newswire / June 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. accessnewswire.com - 1 month ago
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - CYTK NEW YORK, NY / ACCESS Newswire / June 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. accessnewswire.com - 1 month ago
Shareholders that Lost Money on Cytokinetics, Incorporated(CYTK) Should Contact Levi & Korsinsky about Securities Fraud Investigation - CYTK NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. accessnewswire.com - 1 month ago
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program Program to Provide Donations to Non-Profit Organizations  Aligned with Corporate Values Deadline for Applications is August 4 th , 2025 SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for its annual Cytokinetics Corporate Giving Program. globenewswire.com - 1 month ago
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - CYTK NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. accessnewswire.com - 1 month ago
CYTK ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. accessnewswire.com - 1 month ago
Shareholders That Lost Money on Cytokinetics, Incorporated(CYTK) Should Contact Levi & Korsinsky about Securities Fraud Investigation - CYTK NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan. accessnewswire.com - 1 month ago
8. Profile Summary

Cytokinetics, Incorporated CYTK

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 4.42 B
Dividend Yield 0.00%
Description Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Contact 350 Oyster Point Boulevard, South San Francisco, CA, 94080 https://www.cytokinetics.com
IPO Date April 30, 2004
Employees 498
Officers Mr. Robert I. Blum Chief Executive Officer, President & Director Mr. Sung H. Lee EVice President & Chief Financial Officer Mr. Matt Yang Vice President of Corporate Finance and Financial Planning & Analysis Ms. Holly Laughlin Vice President of Accounting & Corporate Controller Ms. Kari K. Loeser J.D. Vice President & Chief Compliance Officer Mr. Andrew M. Callos Executive Vice President & Chief Commercial Officer Mr. Steven M. Cook J.D. Senior Vice President of Global Supply Chain Operations & Technical Operations Mr. Jeff Lotz Vice President of Sales & Operations Dr. James A. Spudich Ph.D. Co-Founder & Member of Scientific Advisory Board Dr. Fady Ibraham Malik FACC, M.D., Ph.D. Executive Vice President of Research & Development